Screener
Vertex Pharmaceuticals VRTX Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Product revenues, net by Product | ||||||
| ALYFTREK | $573.6M+266% | $424.4M+687% | $380.1M— | $247M— | $156.8M— | |
| CASGEVY | $76.4M+151% | $42.9M+202% | $54.3M+579% | $16.9M+745% | $30.4M— | |
| JOURNAVX | $49.6M+313% | $29M+2,131% | $26.7M— | $19.6M— | $12M— | |
| TRIKAFTA/KAFTRIO | $2.5B-2.1% | $2.35B-7.1% | $2.57B-5.5% | $2.65B+2.7% | $2.55B+4.2% |
FAQ
- How does Vertex Pharmaceuticals break its business down?
- Vertex Pharmaceuticals (VRTX) reports product revenues, net by product across 5 parts — ALYFTREK, CASGEVY, JOURNAVX, Other CF product revenues and TRIKAFTA/KAFTRIO. Each is extracted from the segment footnotes and tracked over time.
- Where does Vertex Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Vertex Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
